Can normal tumor markers rule out uterine cancer?

Normal tumor markers cannot completely rule out uterine cancer, and a comprehensive judgment based on imaging examinations and clinical symptoms is still required. Tumor markers are only used as auxiliary diagnostic tools, and normal results do not mean absolute safety. Further screening such as ultrasound, CT, MRI and other imaging examinations as well as tissue biopsy are the key to a confirmed diagnosis.

1. Limitations of tumor markers

Tumor markers such as CA125 and HE4 are often used for screening and monitoring of uterine cancer, but their sensitivity and specificity are limited. Some patients with early uterine cancer may have normal marker levels, while certain benign lesions such as endometriosis may also cause elevated markers. Relying solely on tumor marker results can easily lead to missed or misdiagnosis.

2. Importance of imaging examinations

Imaging examination is an important means of diagnosing uterine cancer. Ultrasound examination can evaluate the thickness and abnormal changes of the endometrium, while CT and MRI can more clearly show the size, location and infiltration of surrounding tissues of the tumor. For suspected cases, enhanced imaging examination can help to detect tiny lesions and improve the accuracy of diagnosis.

3. The diagnostic significance of tissue biopsy

Tissue biopsy is the gold standard for diagnosing uterine cancer. Obtaining endometrial tissue for pathological examination through hysteroscopy or curettage can clarify the nature and stage of the lesion. For patients with abnormal imaging examinations or obvious clinical symptoms, biopsy is an indispensable step.

Normal tumor markers cannot rule out uterine cancer. Diagnosis requires a comprehensive evaluation of imaging examinations and tissue biopsy results. Regular physical examinations and attention to physical changes, such as abnormal vaginal bleeding, lower abdominal pain and other symptoms, and timely medical screening are the key to preventing and early detection of uterine cancer.